通过WGCNA鉴定肺腺癌肿瘤干细胞相关的免疫微环境、突变负担、免疫治疗和药物敏感性。

IF 3.5 4区 医学 Q3 ONCOLOGY
Qi Liu, Liusheng Wu, Meiling Lu, Hao Jia, Xiaoqiang Li
{"title":"通过WGCNA鉴定肺腺癌肿瘤干细胞相关的免疫微环境、突变负担、免疫治疗和药物敏感性。","authors":"Qi Liu, Liusheng Wu, Meiling Lu, Hao Jia, Xiaoqiang Li","doi":"10.2174/0115680096337566250906092330","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze LUAD cases in The Cancer Genome Atlas (TCGA), the mRNA expression-based stemness index (mRNAsi) was used. Models of cancer immunity and LUAD prognosis were developed on the basis of correlations between immune and stem cell genes.</p><p><strong>Methods: </strong>We investigated the differential expression of mRNA dryness index (mRNAsi) in LUAD, survival prognosis, and correlation with clinical parameters. Iden-tify key mRNAsi-related modules and genes by weighted gene co-expression network analysis (WGCNA). Gene set enrichment analysis (GSEA/GSVA) was used to identify stem cell markers and immune-related differentially expressed genes (SC IRGs), and 10 key genes were enriched. Subgroup enrichment, gene mutations, genetic correlated-ness, gene expression, immunity, tumor mutational burden (TMB), and drug sensitivity were further performed in the comprehensive analysis of pivot genes and subgroups.</p><p><strong>Results: </strong>Compared with normal cells, LUAD cells presented significantly greater mRNAsi values through differential expression analysis. The mRNAsi was highly cor-related with clinical parameters (age, sex, and T stage). On the basis of WGCNA, blue-green and brown modules were identified as the most significant modules (including positive and negative correlations) associated with mRNAsi expression. The functions and pathways of the two mRNAsi-related modules were enriched mainly in tumor oc-currence, development, and metastasis. Cox regression analysis was used to identify 30 SCIRGs associated with prognosis by combining the stem cell indices of the DEGs and the immune-related DEGs. A LASSO regression model was constructed after 10 DEGs related to the prognosis of patients with LUAD were detected. There were significant differences between the high-risk and low-risk groups in terms of GSEA/GSVA, im-mune cell correlation, clinical correlation, etc., following model validation (P<0.05).</p><p><strong>Discussion: </strong>There are a total of 10 genes in our study model, including four key pre-dictors: DGRIK2, PTTG1, LGR4, and PDGFB. The other 6 genes need to be further delineated and verified. To date, our research has some limitations and has not been validated in cell or animal experiments. These findings provide a relevant theoretical basis for subsequent experimental research on lung adenocarcinoma stem cells. Further research into these cancer stem cell genes will increase the likelihood that they play a role in cancer. There is an opportunity to use it as a therapeutic target for targeted ther-apy for lung adenocarcinoma in the future.</p><p><strong>Conclusion: </strong>mRNAsi is associated with immunity, which was previously overlooked in the gene analysis of LUAD stem cells. These key genes have a strong overall corre-lation, which can be achieved by inhibiting the stemness characteristics of cancer cells, which may lay the foundation for future research on LUAD.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of the Immune Microenvironment, Mutation Burden, Immunotherapy, and Drug Sensitivity Related to Lung Adenocarcinoma Tumor Stem Cells via WGCNA.\",\"authors\":\"Qi Liu, Liusheng Wu, Meiling Lu, Hao Jia, Xiaoqiang Li\",\"doi\":\"10.2174/0115680096337566250906092330\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To analyze LUAD cases in The Cancer Genome Atlas (TCGA), the mRNA expression-based stemness index (mRNAsi) was used. Models of cancer immunity and LUAD prognosis were developed on the basis of correlations between immune and stem cell genes.</p><p><strong>Methods: </strong>We investigated the differential expression of mRNA dryness index (mRNAsi) in LUAD, survival prognosis, and correlation with clinical parameters. Iden-tify key mRNAsi-related modules and genes by weighted gene co-expression network analysis (WGCNA). Gene set enrichment analysis (GSEA/GSVA) was used to identify stem cell markers and immune-related differentially expressed genes (SC IRGs), and 10 key genes were enriched. Subgroup enrichment, gene mutations, genetic correlated-ness, gene expression, immunity, tumor mutational burden (TMB), and drug sensitivity were further performed in the comprehensive analysis of pivot genes and subgroups.</p><p><strong>Results: </strong>Compared with normal cells, LUAD cells presented significantly greater mRNAsi values through differential expression analysis. The mRNAsi was highly cor-related with clinical parameters (age, sex, and T stage). On the basis of WGCNA, blue-green and brown modules were identified as the most significant modules (including positive and negative correlations) associated with mRNAsi expression. The functions and pathways of the two mRNAsi-related modules were enriched mainly in tumor oc-currence, development, and metastasis. Cox regression analysis was used to identify 30 SCIRGs associated with prognosis by combining the stem cell indices of the DEGs and the immune-related DEGs. A LASSO regression model was constructed after 10 DEGs related to the prognosis of patients with LUAD were detected. There were significant differences between the high-risk and low-risk groups in terms of GSEA/GSVA, im-mune cell correlation, clinical correlation, etc., following model validation (P<0.05).</p><p><strong>Discussion: </strong>There are a total of 10 genes in our study model, including four key pre-dictors: DGRIK2, PTTG1, LGR4, and PDGFB. The other 6 genes need to be further delineated and verified. To date, our research has some limitations and has not been validated in cell or animal experiments. These findings provide a relevant theoretical basis for subsequent experimental research on lung adenocarcinoma stem cells. Further research into these cancer stem cell genes will increase the likelihood that they play a role in cancer. There is an opportunity to use it as a therapeutic target for targeted ther-apy for lung adenocarcinoma in the future.</p><p><strong>Conclusion: </strong>mRNAsi is associated with immunity, which was previously overlooked in the gene analysis of LUAD stem cells. These key genes have a strong overall corre-lation, which can be achieved by inhibiting the stemness characteristics of cancer cells, which may lay the foundation for future research on LUAD.</p>\",\"PeriodicalId\":10816,\"journal\":{\"name\":\"Current cancer drug targets\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current cancer drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115680096337566250906092330\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096337566250906092330","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:采用基于mRNA表达的干性指数(mRNAsi)对癌症基因组图谱(TCGA)中的LUAD病例进行分析。基于免疫和干细胞基因之间的相关性,建立了癌症免疫和LUAD预后的模型。方法:研究mRNA干燥指数(mRNAsi)在LUAD患者中的差异表达、生存预后及与临床参数的相关性。通过加权基因共表达网络分析(WGCNA)确定mrnasi相关的关键模块和基因。采用基因集富集分析(GSEA/GSVA)鉴定干细胞标记物和免疫相关差异表达基因(SC IRGs),富集了10个关键基因。进一步进行亚群富集、基因突变、遗传相关性、基因表达、免疫、肿瘤突变负荷(tumor mutational burden, TMB)、药物敏感性等综合分析。结果:通过差异表达分析,LUAD细胞的mRNAsi值明显高于正常细胞。mRNAsi与临床参数(年龄、性别和T分期)高度相关。在WGCNA的基础上,蓝绿色和棕色模块被确定为与mRNAsi表达相关最显著的模块(包括正相关和负相关)。这两个mrnasi相关模块的功能和通路主要富集于肿瘤的发生、发展和转移。结合DEGs的干细胞指数和免疫相关DEGs,采用Cox回归分析,鉴定出30个与预后相关的SCIRGs。检测与LUAD患者预后相关的10个deg后,构建LASSO回归模型。高危组与低危组在GSEA/GSVA、免疫细胞相关性、临床相关性等方面存在显著性差异,经模型验证(PDiscussion:我们的研究模型共有10个基因,包括4个关键预测因子:DGRIK2、PTTG1、LGR4、PDGFB。其余6个基因有待进一步描述和验证。到目前为止,我们的研究有一些局限性,尚未在细胞或动物实验中得到验证。这些发现为后续肺腺癌干细胞的实验研究提供了相关的理论基础。对这些癌症干细胞基因的进一步研究将增加它们在癌症中发挥作用的可能性。未来有机会将其作为肺腺癌靶向治疗的治疗靶点。结论:mRNAsi与免疫相关,这在以前LUAD干细胞的基因分析中被忽视。这些关键基因具有较强的整体相关性,这可以通过抑制癌细胞的干性特征来实现,这可能为未来LUAD的研究奠定基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identification of the Immune Microenvironment, Mutation Burden, Immunotherapy, and Drug Sensitivity Related to Lung Adenocarcinoma Tumor Stem Cells via WGCNA.

Objective: To analyze LUAD cases in The Cancer Genome Atlas (TCGA), the mRNA expression-based stemness index (mRNAsi) was used. Models of cancer immunity and LUAD prognosis were developed on the basis of correlations between immune and stem cell genes.

Methods: We investigated the differential expression of mRNA dryness index (mRNAsi) in LUAD, survival prognosis, and correlation with clinical parameters. Iden-tify key mRNAsi-related modules and genes by weighted gene co-expression network analysis (WGCNA). Gene set enrichment analysis (GSEA/GSVA) was used to identify stem cell markers and immune-related differentially expressed genes (SC IRGs), and 10 key genes were enriched. Subgroup enrichment, gene mutations, genetic correlated-ness, gene expression, immunity, tumor mutational burden (TMB), and drug sensitivity were further performed in the comprehensive analysis of pivot genes and subgroups.

Results: Compared with normal cells, LUAD cells presented significantly greater mRNAsi values through differential expression analysis. The mRNAsi was highly cor-related with clinical parameters (age, sex, and T stage). On the basis of WGCNA, blue-green and brown modules were identified as the most significant modules (including positive and negative correlations) associated with mRNAsi expression. The functions and pathways of the two mRNAsi-related modules were enriched mainly in tumor oc-currence, development, and metastasis. Cox regression analysis was used to identify 30 SCIRGs associated with prognosis by combining the stem cell indices of the DEGs and the immune-related DEGs. A LASSO regression model was constructed after 10 DEGs related to the prognosis of patients with LUAD were detected. There were significant differences between the high-risk and low-risk groups in terms of GSEA/GSVA, im-mune cell correlation, clinical correlation, etc., following model validation (P<0.05).

Discussion: There are a total of 10 genes in our study model, including four key pre-dictors: DGRIK2, PTTG1, LGR4, and PDGFB. The other 6 genes need to be further delineated and verified. To date, our research has some limitations and has not been validated in cell or animal experiments. These findings provide a relevant theoretical basis for subsequent experimental research on lung adenocarcinoma stem cells. Further research into these cancer stem cell genes will increase the likelihood that they play a role in cancer. There is an opportunity to use it as a therapeutic target for targeted ther-apy for lung adenocarcinoma in the future.

Conclusion: mRNAsi is associated with immunity, which was previously overlooked in the gene analysis of LUAD stem cells. These key genes have a strong overall corre-lation, which can be achieved by inhibiting the stemness characteristics of cancer cells, which may lay the foundation for future research on LUAD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current cancer drug targets
Current cancer drug targets 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
105
审稿时长
1 months
期刊介绍: Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信